Royce & Associates LP Cuts Position in Artivion, Inc. $AORT

Royce & Associates LP trimmed its position in shares of Artivion, Inc. (NYSE:AORT) by 18.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 432,782 shares of the company’s stock after selling 96,965 shares during the period. Royce & Associates LP owned about 0.91% of Artivion worth $19,739,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in AORT. Aster Capital Management DIFC Ltd increased its stake in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after buying an additional 519 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Artivion during the third quarter worth approximately $27,000. Larson Financial Group LLC increased its stake in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the period. Finally, USA Financial Formulas increased its stake in shares of Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AORT. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research note on Thursday, March 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Artivion in a research note on Wednesday, May 20th. Needham & Company LLC cut their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, April 10th. Finally, Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.83.

Insider Transactions at Artivion

In related news, SVP Marshall S. Stanton sold 2,149 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $81,189.22. Following the completion of the transaction, the senior vice president directly owned 60,097 shares of the company’s stock, valued at $2,270,464.66. This represents a 3.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Lance A. Berry sold 6,316 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $238,618.48. Following the completion of the transaction, the executive vice president directly owned 210,827 shares of the company’s stock, valued at $7,965,044.06. This trade represents a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 71,841 shares of company stock valued at $2,722,655 over the last three months. 6.30% of the stock is owned by corporate insiders.

Artivion Stock Performance

Shares of AORT opened at $23.21 on Wednesday. The stock has a 50 day moving average price of $32.83 and a 200 day moving average price of $39.23. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of 96.71 and a beta of 1.41. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.